Plain-English translation of NCT07547787 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a follow-up study for people who already participated in earlier clinical trials testing cadonilimab, a new type of immunotherapy medication for advanced gastric cancer. Rather than giving you a new treatment, this study simply collects information about your health over time to understand whether the medication may provide long-term survival benefits. Researchers want to learn how people fare months and years after receiving this treatment.
Cadonilimab is a newly approved immunotherapy that works in a novel way, and doctors want to track how patients do over the long term to confirm whether this medication truly helps people with gastric cancer live longer and better.
You likely qualify if…
You likely don't qualify if…
You would continue to be monitored and share information about your health status over time — this is not a treatment study, so you won't receive the medication again. Instead, researchers will gather data about how you are doing, possibly through medical visits, phone calls, or review of your medical records. The study is designed to be minimally burdensome, and you are allowed to participate in other clinical trials at the same time.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Enrollment target
~610 participants
Started
December 2024
Primary completion
December 2030
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhifang Yao，MD
Peking University Cancer Hospital & Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.